Condition or Therapy: Lymphocytic leukemia, acute myeloid leukemia, chronic myelogenous leukemia
Category: Cancer and Blood Disorders

What is the goal of this study?

When patients receive a stem cell transplant from a donor they can sometimes develop graft-versus-host disease (GVHD). This happens when the donated T cells attack a patient’s body, including the skin, liver, kidneys, lungs, and other organs.

In this phase 2 trial, researchers want to find out if removing the group of T cells that are responsible for GVHD before they are given to patients will prevent them from getting GVHD.

Who can join the study?

This study might be a good fit for children and adults who: 

  • Are ages 0 to 60 years old
  • Are candidates for an allogeneic hematopoietic stem cell transplant for acute lymphocytic leukemia, acute myeloid leukemia, or chronic myelogenous leukemia

You can read more about the eligibility criteria for this study on clinicaltrials.gov.

Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for you or your child.

What happens in the study?

You can read about the study protocol on clinicaltrials.gov.

Who can I contact for information or to enroll?

Please email the research coordinator for more information about this study.


Study Location(s): Seattle Children's Hospital main campus
Principal Investigator: Dr. Marie Bleakley